Novo Nordisk strengthens board after turbulent year
Changes to Novo Nordisk’s board continue. Following last year’s sweeping restructuring, the Danish obesity drugmaker is now nominating two new directors with extensive experience in the pharmaceutical industry.
The nominations are the first additions since the major overhaul carried out in 2024.
Ahead of the annual general meeting on 26 March, Jan van de Winkel, co-founder and chief executive of Danish biotech Genmab, and Ramona Sequeira, former head of the Global Portfolio Division at Japan’s Takeda Pharmaceutical, are being proposed as new board members, according to a press release.
News in English
BREAKING